Application Detail
Description of Medical Service
Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.Description of Medical Condition
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin Lymphoma (NHL).Reason for Application
Minor changes to the MSAC eligibility criteria are requested:- to allow TFL patients who have undergone prior autologous stem cell transplant (ASCT) to access tisagenlecleucel, without the requirement for additional systemic therapy post-ASCT; and
- that grade 3B FL patients be considered as DLBCL in the eligibility criteria due to the similarity of grade 3B FL to DLBCL in terms of presentation, behaviour and outcomes.
Medical Service Type
Hybrid health technologyPrevious Application Number/s
1519, 1519.1Associated Documentation
Application Form
Not applicableConsultation Survey
Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1676 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).Public Summary Document
Public Summary Document (PDF 495 KB)Public Summary Document (Word 153 KB)